The cost to develop a new drug is every expensive, exceeding $2.6 billion. It normally takes over 15-20 years from the drug screening, lab testing, animal studies, Phase 1, Phase 1 and Phase 3 and the stringent FDA regulatory process.

Recent advances in artificial intelligence (AI) may help to reverse this trend and accelerate and improve pharmaceutical research and development.

Biomed AI algorithms are designed to analyze vast amounts of data quickly and accurately, enabling us to identify potential candidates for clinical trials from electronic health records, medical images, and other sources.

To improve screening, we are developing AI algorithms that can predict potential issues early on, identifying potential safety concerns and providing insights into the efficacy of treatments. This enables our researchers to make data-driven decisions on which drugs to pursue further, improving the quality of the data generated during clinical trials and reducing the risk of enrollment of ineligible participants.